XBiotech (XBIT) Competitors $3.62 +0.01 (+0.28%) Closing price 04:00 PM EasternExtended Trading$3.67 +0.05 (+1.38%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends XBIT vs. RAPP, GHRS, TRML, MLYS, ARCT, CDXC, AKBA, ANNX, SIGA, and MREOShould you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Rapport Therapeutics (RAPP), GH Research (GHRS), Tourmaline Bio (TRML), Mineralys Therapeutics (MLYS), Arcturus Therapeutics (ARCT), ChromaDex (CDXC), Akebia Therapeutics (AKBA), Annexon (ANNX), SIGA Technologies (SIGA), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. XBiotech vs. Rapport Therapeutics GH Research Tourmaline Bio Mineralys Therapeutics Arcturus Therapeutics ChromaDex Akebia Therapeutics Annexon SIGA Technologies Mereo BioPharma Group Rapport Therapeutics (NASDAQ:RAPP) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Does the MarketBeat Community prefer RAPP or XBIT? XBiotech received 315 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 69.98% of users gave XBiotech an outperform vote. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesXBiotechOutperform Votes31769.98% Underperform Votes13630.02% Is RAPP or XBIT more profitable? Rapport Therapeutics' return on equity of 0.00% beat XBiotech's return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A XBiotech N/A -15.99%-14.85% Which has higher valuation and earnings, RAPP or XBIT? XBiotech has higher revenue and earnings than Rapport Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79MN/AN/AXBiotech$4.01M27.52-$24.56M-$1.08-3.35 Does the media favor RAPP or XBIT? In the previous week, Rapport Therapeutics had 2 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Rapport Therapeutics and 2 mentions for XBiotech. Rapport Therapeutics' average media sentiment score of 0.64 beat XBiotech's score of 0.08 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of RAPP or XBIT? 55.7% of XBiotech shares are held by institutional investors. 33.1% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend RAPP or XBIT? Rapport Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 110.21%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Rapport Therapeutics is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRapport Therapeutics beats XBiotech on 8 of the 13 factors compared between the two stocks. Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIT vs. The Competition Export to ExcelMetricXBiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.34M$6.92B$5.62B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E Ratio-3.3510.1189.6917.66Price / Sales27.52351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book0.505.335.134.73Net Income-$24.56M$157.56M$118.85M$225.42M7 Day Performance-2.16%2.83%1.87%-0.44%1 Month Performance-11.49%2.84%7.96%3.57%1 Year Performance-16.59%8.37%26.70%19.20% XBiotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBITXBiotech0.5746 of 5 stars$3.62+0.3%N/A-16.0%$110.34M$4.01M-3.35100RAPPRapport Therapeutics2.6029 of 5 stars$12.69+1.4%$35.00+175.8%N/A$464.20MN/A0.00N/AUpcoming EarningsShort Interest ↓News CoverageGHRSGH Research1.9752 of 5 stars$8.88+3.3%$35.67+301.7%+27.3%$462.03MN/A-11.2410Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageTRMLTourmaline Bio1.6788 of 5 stars$18.00+3.9%$54.00+200.0%-55.3%$461.52MN/A-6.3844Short Interest ↑MLYSMineralys Therapeutics2.7595 of 5 stars$9.24-2.7%$30.00+224.7%-5.3%$459.88MN/A-2.8328Positive NewsARCTArcturus Therapeutics2.27 of 5 stars$16.79-1.3%$66.75+297.6%-49.9%$454.84M$169.93M-7.56180Analyst ForecastShort Interest ↑CDXCChromaDex4.707 of 5 stars$5.94+5.1%$8.00+34.7%+280.6%$453.72M$91.67M594.59120Short Interest ↑AKBAAkebia Therapeutics3.6567 of 5 stars$2.07+7.3%$7.50+262.3%+28.5%$451.64M$169.88M-9.00430Short Interest ↑High Trading VolumeANNXAnnexon2.1514 of 5 stars$4.20+2.2%$15.80+276.2%-11.4%$447.68MN/A-4.0060Short Interest ↑SIGASIGA Technologies2.2586 of 5 stars$6.22-0.3%N/A+24.2%$444.11M$139.92M5.1840Positive NewsMREOMereo BioPharma Group3.231 of 5 stars$2.86-1.4%$7.83+173.9%-27.7%$443.73M$10M0.0040 Related Companies and Tools Related Companies RAPP Competitors GHRS Competitors TRML Competitors MLYS Competitors ARCT Competitors CDXC Competitors AKBA Competitors ANNX Competitors SIGA Competitors MREO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XBIT) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
